FINHUB Insights

GILD · Q3 FY25 · Jul 1 – Sep 30, 2025

Gilead Sciences Q3 FY25: where the revenue came from and where it went

Gilead Sciences Q3 FY25: revenue $7.8B (+3% year over year). Net profit $3.1B. Largest cohort Biktarvy $3.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 7, 2025 10-Q
Sankey diagram of Gilead Sciences's income statement for Q3 FY25: revenue of $7.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$7.8B +3% year over year
Gross profit$6.2B 80% margin
Operating profit$3.3B 43% margin
Net profit$3.1B 39% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 7.8 100% +3%
Biktarvy 3.7 47%
Other 1.4 18%
Descovy 0.7 9%
Total Cell Therapy 0.4 5%
Royalty, contract and other 0.4 5%
Genvoya 0.4 5%
Trodelvy 0.4 5%
Yescarta 0.3 4%
Cost of revenue−1.621%
Gross profit6.280% margin+1pp
SG&A−1.417%−2pp
Other−1.520%+0pp
Operating profit3.343% margin+31pp
Tax−0.5
Net profit3.139%+23pp
Filing on EDGAR More quarters of GILD

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters